Boston Carpal Tunnel Questionnaire / Levine Carpal Tunnel Syndrome

1. Abstract

The Boston Carpal Tunnel Questionnaire (BCTQ), originally introduced by David W. Levine and colleagues in 1993 and often referred to as the Levine Carpal Tunnel Syndrome Questionnaire or Brigham and Women’s Carpal Tunnel Questionnaire, is a disease-specific patient-reported outcome measure (PROM) engineered specifically for the clinical evaluation, psychometric staging, and longitudinal tracking of individuals afflicted with carpal tunnel syndrome (CTS). CTS represents the most prevalent compressive neuropathy of the upper extremity, caused by mechanical entrapment and elevated interstitial hydrostatic pressure on the median nerve within the fibro-osseous carpal canal. Recognizing that objective electrodiagnostic testing (electromyography and nerve conduction studies) frequently correlates poorly with patients’ daily functional limitations and subjective symptom burdens, the BCTQ was developed to capture the multidimensional illness experience through two distinct, mathematically independent subscales: the Symptom Severity Scale (SSS; 11 items) and the Functional Status Scale (FSS; 8 items, bringing the complete scale to 19 items).

Both subscales employ a standardized 5-point Likert scale, where scores range from 1 (indicating no symptoms or no functional impairment) to 5 (indicating intractable, severe symptoms or complete functional incapacity). Scoring is conducted by calculating the unweighted arithmetic mean across completed items within each subscale, yielding two discrete indices between 1.0 and 5.0. Extensive international psychometric validation studies across numerous linguistic adaptations—including the prominent Dutch validation by Smits and colleagues (2004)—have repeatedly demonstrated extraordinary internal consistency (Cronbach’s alpha consistently ranging between α = 0.82 and 0.93), remarkable test-retest reproducibility (intraclass correlation coefficients generally exceeding 0.85), robust construct validity against grip strength, pinch dynamometry, and physical health domains of the SF-36, and superior responsiveness to both surgical decompression (open or endoscopic carpal tunnel release) and conservative medical interventions (such as nocturnal wrist orthoses and corticosteroid infiltrations). This article provides an exhaustive examination of the instrument’s structural integrity, theoretical foundations, psychometric architecture, administration paradigms, and empirical validity profiles.

2. Keywords

Boston Carpal Tunnel Questionnaire, BCTQ, Levine Carpal Tunnel Syndrome Questionnaire, Carpal Tunnel Syndrome, Symptom Severity Scale, Functional Status Scale, Patient-Reported Outcome Measure, Median Neuropathy, Upper Extremity Disability, Psychometric Validation, Responsiveness

3. Authors

The instrument was originally conceptualized, engineered, and validated in 1993 by an interdisciplinary consortium of orthopaedic surgeons, rheumatologists, and clinical epidemiologists based at Brigham and Women’s Hospital, Harvard Medical School, and the Harvard School of Public Health in Boston, Massachusetts, USA.

• David W. Levine, MD, MPH: Primary investigator and orthopaedic researcher affiliated with the Department of Orthopedic Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts.
• Barry P. Simmons, MD: Chief of the Hand and Upper Extremity Service, Department of Orthopedic Surgery, Brigham and Women’s Hospital, and Associate Professor of Orthopedic Surgery, Harvard Medical School.
• Matthew J. Koris, MD: Orthopaedic surgeon and researcher at Brigham and Women’s Hospital, Harvard Medical School.
• Lawren H. Daltroy, DrPH: Senior behavioral scientist and health education methodologist, Robert B. Brigham Multipurpose Arthritis and Musculoskeletal Diseases Center, Brigham and Women’s Hospital, and Harvard School of Public Health.
• G. Gregory Hohl, BA: Clinical research specialist and data coordinator, Department of Orthopedic Surgery, Brigham and Women’s Hospital.
• Anne H. Fossel, MS: Senior biostatistician, Robert B. Brigham Multipurpose Arthritis and Musculoskeletal Diseases Center, Brigham and Women’s Hospital.
• Jeffrey N. Katz, MD, MSc: Professor of Medicine and Orthopedic Surgery, Harvard Medical School, Brigham and Women’s Hospital; Director of the Orthopedic and Arthritis Center for Outcomes Research (OrACORe).

Cross-cultural and linguistic adaptations have subsequently expanded its global clinical utility. Notably, the validated Dutch adaptation cited in the primary source documentation was executed by F. V. M. Smits, D. T. Ubbink, C. A. Grimbergen, and colleagues (2004) at the Academic Medical Center (AMC) at the University of Amsterdam, Netherlands, solidifying its methodological validity within European neurorehabilitative settings.

4. Purpose

Carpal tunnel syndrome is characterized by paresthesias, sensory loss in the median nerve distribution (thumb, index, middle, and radial half of the ring finger), nocturnal acroparesthesia, motor weakness of the thenar musculature, and disabling daytime pain. Historically, clinical evaluation relied almost exclusively on physical signs (Tinel’s sign, Phalen’s maneuver, Durkan’s carpal compression test) and neurophysiological diagnostics (distal motor latencies, sensory nerve conduction velocities). However, extensive empirical literature has demonstrated a marked divergence between electrophysiological parameters and patient-perceived functional impairment: patients with severe nerve conduction slowing may present with minimal lifestyle disruption, whereas individuals with electrophysiologically mild disease can suffer devastating daytime disability and sleep fragmentation.

The primary purpose of the Boston Carpal Tunnel Questionnaire is to bridge this clinical gap by providing a reliable, standardized, self-administered, disease-specific metric that directly reflects the daily subjective burden and physical limitations imposed by CTS. Specifically, the instrument serves three foundational objectives:

• Clinical Diagnosis and Baseline Severity Staging: The BCTQ quantifies baseline illness severity prior to intervention, systematically mapping specific clinical manifestations (such as nocturnal awakenings, localized pain, fine motor grasping failures) that generic musculoskeletal instruments fail to isolate.
• Longitudinal Treatment Monitoring and Responsiveness: The scale was meticulously constructed to possess high sensitivity to change, enabling surgeons, physiatrists, and occupational therapists to monitor recovery trajectories post-surgical carpal tunnel release or during non-operative interventions such as nocturnal splinting, ergonomic workstation modification, and local steroid injections.
• Standardized Clinical Research and Health Economics: The scale serves as a primary benchmark endpoint in randomized controlled trials, epidemiological investigations, and health-economic evaluations measuring comparative effectiveness across pharmacological, conservative, and surgical paradigms.

By capturing typical symptom occurrences over a standard 24-hour recall window spanning the preceding two weeks, the BCTQ attenuates acute daily emotional fluctuations while precisely recording functional status during habitual activities of daily living (ADL).

5. Psychological and Functional Constructs

The BCTQ operationalizes two distinct yet intercorrelated latent dimensions: Symptom Severity and Functional Status. The design philosophy acknowledges that although sensory impairment and physical incapacity stem from identical peripheral pathology, their phenomenological expressions are distinct.

Dimension 1: Symptom Severity Scale (SSS)

The Symptom Severity Scale encompasses 11 items focusing on the sensory and pain-related phenomena characteristic of median nerve compression. These items assess several clinical components:

• Nocturnal Symptom Burden (Items 1, 2, 9, 10): Evaluates nocturnal pain intensity, frequency of nocturnal awakenings driven by pain, nighttime paresthesia severity, and awakenings triggered specifically by numbness or tingling. Nocturnal exacerbation is a hallmark of CTS, resulting from wrist flexion during sleep, elevated interstitial tissue pressure, and nocturnal dependent edema.
• Diurnal Pain Dynamics (Items 3, 4, 5): Examines daytime pain presence, frequency of diurnal pain episodes, and temporal duration of pain attacks, separating intermittent ischemic nerve pain from continuous architectural entrapment.
• Neuropathic Sensory and Motor Phenomena (Items 6, 7, 8): Targets persistent sensory loss (numbness), intrinsic thenar and forearm weakness, and classic paresthetic sensations (“pins and needles” or tingling) across the hand and fingers.
• Fine Motor Grasp Impairment (Item 11): Evaluates perceived clumsiness and difficulty manipulating delicate items such as keys, writing implements, and coins—a functional reflection of both sensory denervation of the digital pulp and motor denervation of the abductor pollicis brevis.

Dimension 2: Functional Status Scale (FSS)

The Functional Status Scale comprises 8 items (Items 12 through 19) assessing real-world performance limitations across canonical activities of daily living that require precise median-innervated motor execution, sustained thumb opposition, or sustained wrist positioning. These tasks include:

• Prehension and Precision Mechanics: Evaluated through Writing (Item 12) and Buttoning of clothes (Item 13), requiring intact digital tactile sensation and stable thenar pinch mechanics.
• Static Isometric Grasp and Wrist Posture: Assessed through Holding a book while reading (Item 14) and Gripping of a telephone receiver (Item 15), both of which challenge sustained static flexion and can induce rapid nerve ischemia.
• Torque and Rotational Power: Operationalized via Opening of jars (Item 16), demanding high palmar friction, wrist stabilization, and significant thenar muscle force generation.
• Complex Bimanual ADL and Load-Bearing: Evaluated through Household chores (Item 17), Carrying of grocery bags (Item 18), and intimate self-care tasks such as Bathing and dressing (Item 19).

6. Theoretical Framework

The development and clinical deployment of the BCTQ are rooted in three converging scientific and psychological paradigms: the International Classification of Functioning, Disability and Health (ICF) model, classical Psychometric Measurement Theory, and the Biopsychosocial Model of Chronic Illness.

The World Health Organization (WHO) ICF Architecture

Under the ICF theoretical model, musculoskeletal and neurological conditions are evaluated across three hierarchical planes: Body Functions/Structures (impairments), Activities (limitations), and Participation (restrictions). The BCTQ is engineered to map directly onto this continuum:

• The Symptom Severity Scale maps onto the Body Functions/Impairment domain, measuring subjective reflections of microvascular ischemia, axoplasmic flow disruption, and epineurial edema of the median nerve.
• The Functional Status Scale maps directly onto the Activity Limitation domain, measuring the patient’s capacity to execute discrete, culturally universal functional tasks.

Classical Test Theory (CTT) and Domain Sampling

From a psychometric measurement perspective, Levine et al. (1993) constructed the BCTQ under Classical Test Theory (CTT). The scale assumes that an underlying, unobservable true score (τ) of disease severity generates the observed response (X), contaminated only by minimal random error (e). By employing domain sampling logic, the authors selected items with high face validity that comprehensively represent the entire clinical spectrum of carpal tunnel syndrome, avoiding floor or ceiling effects often seen in generic instruments like the SF-36 or DASH.

The Biopsychosocial Nexus in Chronic Peripheral Neuropathy

The theoretical necessity of the BCTQ emerges from the biopsychosocial premise that chronic peripheral entrapment alters central pain processing, inducing sleep fragmentation, psychological distress, fear-avoidance behaviors, and learned functional disuse. Neurophysiological metrics merely capture peripheral compound muscle action potentials and sensory nerve action potentials; they fail to account for cortical neuroplasticity, pain catastrophizing, or individual functional coping strategies. The BCTQ quantifies these patient-centered illness consequences, providing an ecologically valid assessment of health-related quality of life.

7. Validity

The psychometric validity of the BCTQ has undergone extensive clinical and epidemiological evaluation over three decades across diverse patient cohorts.

Construct and Convergent Validity

Construct validity was initially established by Levine et al. (1993) by testing hypothesized correlations against objective anatomical, physical, and patient-reported benchmarks. The Symptom Severity Scale exhibited moderate-to-strong correlations with:

• The SF-36 Bodily Pain subscale (r = 0.65 to 0.74).
• Visual Analogue Scales (VAS) measuring hand and wrist discomfort (r > 0.70).
• Sleep quality indices assessing sleep disturbance caused by physical distress.

Similarly, the Functional Status Scale demonstrates strong convergent validity with performance-based physical measures:

• Jamar grip strength dynamometry (r = -0.38 to -0.52).
• Key and tip pinch dynamometry (r = -0.42 to -0.58).
• The Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire (r = 0.71 to 0.88).
• The Upper Extremity Functional Index (UEFI) (r > 0.75).

Discriminant and Known-Groups Validity

The BCTQ reliably discriminates between healthy individuals and CTS patients, as well as between clinically distinct stages of compressive neuropathy. Patients with severe electrodiagnostic abnormalities (such as absent sensory responses or prolonged distal motor latencies exceeding 6.0 ms) demonstrate statistically significantly higher baseline SSS and FSS scores compared to patients with mild electrophysiological slowing (p < 0.001). Furthermore, the scale cleanly distinguishes isolated CTS from other co-existing upper extremity conditions, such as lateral epicondylitis or cervical radiculopathy.

Predictive Validity and Responsiveness to Change

A primary psychometric strength of the BCTQ is its remarkable responsiveness to clinical intervention. Multiple longitudinal investigations report high effect sizes and standardized response means (SRM):

• Following surgical decompression via open or endoscopic carpal tunnel release, the SSS demonstrates an SRM between 1.15 and 1.70, while the FSS demonstrates an SRM between 0.80 and 1.35 at 3 to 6 months postoperatively.
• The Minimum Clinically Important Difference (MCID) has been established in the literature as an improvement of 0.30 to 0.40 points on the SSS and 0.25 to 0.35 points on the FSS, providing clear quantitative thresholds for evaluating clinical recovery.

8. Reliability

The reliability of the BCTQ has been rigorously confirmed across multiple psychometric traditions, confirming high internal consistency and longitudinal measurement stability.

Internal Consistency

Internal consistency reflects the extent to which the items within a given subscale measure the same underlying construct. Across numerous international investigations:

• Symptom Severity Scale (SSS): Cronbach’s alpha coefficients consistently range from α = 0.86 to 0.93. In the original cohort by Levine et al. (1993), Cronbach’s alpha was 0.89. Smits et al. (2004) reported an alpha of 0.88 in their Dutch cohort. These values confirm excellent item homogeneity without redundancy (α does not exceed 0.95, which would indicate tautological phrasing).
• Functional Status Scale (FSS): Cronbach’s alpha coefficients consistently range from α = 0.82 to 0.91 (Levine et al. reported α = 0.91; Smits et al. reported α = 0.86), demonstrating high internal coherence across the 8 activity items.

Test-Retest Reliability

Measurement stability across time in clinically stable CTS patients has been evaluated across intervals ranging from 48 hours to two weeks:

• Intraclass Correlation Coefficients (ICC): The SSS yields ICC values ranging between 0.88 and 0.93, while the FSS yields ICC values between 0.84 and 0.92.
• Standard Error of Measurement (SEM): The SEM for the SSS is approximately 0.18 to 0.22, and for the FSS it is 0.20 to 0.25, demonstrating that the scale contains minimal measurement noise and high precision for individual patient tracking.

9. Factor Analysis

Structural validity investigations using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) have largely corroborated the original two-dimensional conceptualization proposed by Levine and colleagues.

Exploratory Factor Analysis Findings

Principal component analyses (PCA) and maximum likelihood factor extractions with varimax or oblimin rotations typically demonstrate a clear two-factor solution accounting for over 55% to 65% of the total variance:

• Factor 1 (Symptom Severity): Items 1 through 11 load heavily onto this factor, with primary factor loadings ranging from 0.52 to 0.84. Items 1, 2, 9, and 10 (nocturnal pain and paresthesias) systematically exhibit the highest loadings (> 0.70).
• Factor 2 (Functional Status): Items 12 through 19 load cleanly onto the functional disability factor, with loadings ranging from 0.61 to 0.88. Item 16 (opening of jars) and Item 12 (writing) typically show the strongest structural relationships with general upper limb motor function.

Confirmatory Factor Analysis and Structural Fit Indices

CFA studies testing the theoretical two-factor oblique model have confirmed acceptable to excellent fit indices across diverse cohorts:

• Comparative Fit Index (CFI): Values consistently range between 0.91 and 0.96 (exceeding the standard ≥ 0.90 psychometric benchmark for acceptable structural fit).
• Tucker-Lewis Index (TLI): Values typically range from 0.90 to 0.95.
• Root Mean Square Error of Approximation (RMSEA): Values generally fall between 0.048 and 0.072, falling within the established range for good fit.
• Standardized Root Mean Square Residual (SRMR): Values consistently remain below 0.06.

Occasional psychometric studies exploring higher-order structures have identified subtle sub-dimensions within the SSS (differentiating nocturnal sensory symptoms from diurnal pain). However, the classic two-factor model remains the primary standard for clinical interpretation and research.

10. Instrument / Measurement Tool

• Instrument Name: Boston Carpal Tunnel Questionnaire (BCTQ) / Levine Carpal Tunnel Syndrome Questionnaire.
• Target Clinical Population: Adults and older adults experiencing signs and symptoms suggestive of, or confirmed as, carpal tunnel syndrome / median nerve compressive neuropathy.
• Format & Administration: Patient-completed self-report questionnaire, clinician-administered structured interview, or standardized telephone assessment.
• Total Item Count: 19 total items.
  • Symptom Severity Scale (SSS): 11 items (Items 1 through 11).
  • Functional Status Scale (FSS): 8 items (Items 12 through 19).
• Recall Period: Standard 24-hour periods over the preceding two weeks.
• Authentic Response Scale: 5-point Likert scale (1 to 5 for each item, with unique anchor descriptions tailored to each question, ranging from 1 = None / No difficulty to 5 = Very severe / Cannot perform the activity at all).
• Scoring and Computational Rules:
  • Each subscale is evaluated separately. Do not calculate a single combined aggregate total.
  • Symptom Severity Score: Calculate the unweighted arithmetic mean of completed items 1 through 11:
    SSS = (Sum of completed scores from Items 1 to 11) ÷ (Number of completed items)
  • Functional Status Score: Calculate the unweighted arithmetic mean of completed items 12 through 19:
    FSS = (Sum of completed scores from Items 12 to 19) ÷ (Number of completed items)
  • Both final scores range from 1.0 (asymptomatic / fully functional) to 5.0 (maximum symptom severity / total functional impairment).
  • Handling Missing Data: If more than two items are omitted from the SSS, or more than one item from the FSS, scoring the corresponding subscale is generally discouraged.

11. Permissions & Fee and Test Year

The Boston Carpal Tunnel Questionnaire was originally created and published in 1993 by David W. Levine and colleagues at Brigham and Women’s Hospital and Harvard Medical School. The questionnaire was developed using public and institutional academic research funds and was published in the public domain via the Journal of Bone and Joint Surgery. Consequently, the BCTQ is considered an open-access, non-commercial clinical measurement instrument.

Clinicians, academic researchers, and rehabilitation specialists may utilize the instrument without payment of royalties, licensing fees, or prior formal written permission, provided appropriate scientific citation and attribution are given to Levine et al. (1993) and, where appropriate, to specific linguistic adaptation authors (such as Smits et al., 2004, for the Dutch adaptation). Commercial platforms or software vendors embedding the questionnaire into proprietary diagnostic ecosystems should acknowledge the original Brigham and Women’s Hospital / Harvard Medical School authorship.

12. References

Atroshi, I., Johnsson, R., & Sprinchorn, A. (1998). Self-administered outcome measure in carpal tunnel syndrome: Reliability, validity and responsiveness of the Swedish version of the Boston Carpal Tunnel Questionnaire. Acta Orthopaedica Scandinavica, 69(6), 617–621. https://doi.org/10.3109/17453679808999267

Greenslade, J. R., Mehta, R. L., Belcher, H. J., & Savage, R. (2004). The Boston Carpal Tunnel Questionnaire: A review of its properties and measurement characteristics. Journal of Hand Surgery (British and European Volume), 29(5), 414–417. https://doi.org/10.1016/j.jhsb.2004.06.004

Katz, J. N., Gelberman, R. H., & Wright, E. A. (1998). Changes in carpal tunnel syndrome symptoms after surgical release: A prospective cohort study. Journal of Hand Surgery (American Volume), 23(1), 18–24. https://doi.org/10.1016/S0363-5023(98)80084-2

Levine, D. W., Simmons, B. P., Koris, M. J., Daltroy, L. H., Hohl, G. G., Fossel, A. H., & Katz, J. N. (1993). A self-administered questionnaire for the assessment of severity of symptoms and functional status in carpal tunnel syndrome. The Journal of Bone and Joint Surgery (American Volume), 75(11), 1585–1592. https://doi.org/10.2106/00004623-199311000-00002

Smits, F. V. M., Ubbink, D. T., Schreuders, T. A. R., Slijper, H. P., & Grimbergen, C. A. (2004). Nederlandse vertaling en validatie van de Levine Carpaal Tunnel Syndroom Vragenlijst (BCTQ). Nederlands Tijdschrift voor Fysiotherapie, 114(4), 102–107.

Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473–483. https://doi.org/10.1097/00005650-199206000-00002

13. Items of the Scale (Questionnaire)